Procedures & recovery · patient guide

After Lymphoma Treatment in China: Sharing Treatment and Follow-Up Information

If you received lymphoma treatment in China and are returning home, the practical task is a clean handover: a written summary of the exact lymphoma type, the treatment actually given, response assessments, unresolved results and the follow-up plan. Your receiving clinician decides what to accept and what to repeat. Ask the China team for a structured discharge summary and copies of key reports before you leave.

Go to the practical guidance ↓
AI illustration: A doctor discusses medical information with a couple in a consultation room.
AI-generated illustration for care planning; not a photograph of a real patient, clinician or hospital, and not a diagnostic image.
In this guide

Why the exact lymphoma diagnosis matters in a handover

Lymphoma is not one disease. The National Cancer Institute describes lymphoma as including Hodgkin and non-Hodgkin types, and the exact diagnosis matters when treatment is discussed. That is why a handover that says only 'lymphoma' is not enough for the clinician who will follow you at home.

The receiving clinician needs the pathology report that names the subtype, the tissue or cell source, and any markers or molecular findings that were used to classify it. If the diagnosis was refined during treatment, the later report matters more than the first one. Ask the China team which report is the final diagnostic version and whether a pathology re-review was done.

This is not about doubting the original diagnosis. It is about giving the next clinician the same starting point your China team had, so follow-up decisions are made on the same facts.

The treatment record: what was actually given

A discharge summary should state the treatment your team actually delivered, not only the plan. For lymphoma this may include systemic therapy, radiotherapy, or a period of observation, depending on the subtype and stage. The summary should identify the agents or regimens used, the dates of each block of treatment, and any dose changes or delays with the reason recorded.

Ask for the cumulative doses of any drugs where total exposure matters for later monitoring. Ask whether any treatment was stopped early, and why. If surgery was part of staging or diagnosis, include the operative note and the pathology from that specimen.

If you received radiotherapy, the handover should include the treated area, the total dose and the fractionation, and the date treatment finished. These details affect what the receiving clinician will look for later, so they should be in writing rather than recalled from memory.

Response assessment and unresolved results

The most useful handover answers one question: how did the lymphoma respond to what was given? Include the imaging or other assessments used to judge response, the date of the final assessment, and the conclusion your China team recorded. If a scan was reported as partial response or uncertain, say so plainly rather than summarising it as 'good'.

Unresolved results are just as important. If a test was ordered but the result was pending at discharge, list it, note where the sample was sent, and ask how the result will reach you and your home clinician. If a result was received after you left, the China team may be able to send it on.

Ask whether any findings were flagged for later review, such as a borderline laboratory value, an incidental imaging finding, or a symptom that was being watched. These are the items most likely to be lost in a handover.

What the receiving clinician decides, and what you should ask

Your home clinician decides what to accept, what to repeat and what to monitor. That is normal and appropriate. A records-based review in China cannot confirm acceptance by a hospital in your home country, and it cannot establish that a particular follow-up plan will be approved there.

Before you leave China, ask the China team for a structured discharge summary in English, copies of the pathology and imaging reports, and a written follow-up plan with the intended intervals and the tests proposed. Ask who to contact if a question arises after you return home, and how records can be requested later.

When you meet your home clinician, ask directly: which parts of this record do you accept, which do you want repeated, and what will you monitor? Ask whether the pathology needs re-review and whether any imaging needs to be repeated locally. Ask what symptoms should prompt you to contact the clinic urgently.

Communication and responsibilities after you return home

A handover works best when someone is named on each side. Ask the China team to identify a contact for record requests, and give your home clinic that name and the hospital's contact details. If your home clinician wants to speak with the China team, ask whether that is possible and how it would be arranged.

Keep your own copy of the records. A simple folder with the discharge summary, pathology report, treatment record, final response assessment and the follow-up plan will answer most questions at a first appointment. If you need additional records later, request them in writing and keep the request.

Responsibilities are straightforward: the China team provides the record of what was done; your home clinician provides ongoing assessment and decisions. Neither replaces the other, and neither can guarantee what the other will do.

Practical preparation before you leave China

Start the handover before your last appointment, not on the way to the airport. Ask for the discharge summary and key reports while your team is still available. Check that names, dates and the lymphoma subtype are consistent across documents.

A discharge summary written for a reader at home should stand on its own. Ask the China team to spell out abbreviations, give drug names in full rather than by acronym, and state units for laboratory values. If a report is in Chinese only, ask whether an English version or a translated summary can be provided, and who prepares it.

Ask how the records will be given to you: printed copies, a sealed envelope, a USB drive, or a hospital portal you can still access from abroad. Confirm that any portal login will keep working after discharge, and download what you need before you leave. If you want a copy sent directly to your home clinic, ask whether that is possible and what authorisation it requires.

Ask what the China team will send, to whom, and when. If a final pathology addendum or a pending laboratory result is expected after discharge, ask who will forward it and how you will be told. Give the team your home clinic's address and a contact name if you have one.

Keep the records with you rather than in checked luggage. A single folder with the discharge summary, pathology report, treatment record, final response assessment and follow-up plan answers most questions at a first appointment at home.

If you want a records-based opinion on the follow-up plan before your home appointment, that is a separate step from the handover itself. An initial enquiry is free and asks for a brief summary, not a complete archive.

For lymphoma-specific planning in China, the relevant reference is the lymphoma treatment page. Use it to understand the service scope, then confirm your own records and questions with the treating team.

Related treatment reference

Sources & scope of this guide

References and official service information relevant to this guide.

  1. radiotherapy
  2. Related treatment reference
  3. NCI: Lymphoma Patient Version

This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.